SharadKumarJainMD

Oncology • Denton, TX

Physician

Join to view full profile

Dr. Jain is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Jain's full profile

Already have an account?

Office
3720 S I-35 E
Denton, TX 76210
Phone+1 940-382-1022

Fax+1 940-380-7904
Is this information wrong?

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 1990 - 1992
University at BuffaloResidency, Internal Medicine, 1989 - 1990
Maulana Azad Medical CollegeClass of 1981

Certifications & Licensure

AZ State Medical License 1995 - Present
TX State Medical License 2001 - 2024
PA State Medical License 1991 - 1998
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Start of enrollment: 2015 Dec 28
Completed
Phase 3
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Rosai-Dorfman disease in a symptomatic elderly man
Gaurav Synghal, Risha Bhavan, Sharad Jain, Umesh Oza> ;Proceedings. 2021 Aug 12
81 citations
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Chung-Han Lee, Amishi Yogesh Shah, Drew W. Rasco, Arpit Rao, Matthew H. Taylor, Christopher Di Simone, James J. Hsieh, Alvaro Pinto, David R. Shaffer, Regina Gironés S...> ;The Lancet. Oncology. 2021 Jul 1

Hospital Affiliations

Medical City DentonDenton, Texas
Texas Health Presbyterian Hospital DentonDenton, Texas
Medical City LewisvilleLewisville, Texas